<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with long-term <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD), <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) and Crohn's <z:e sem="disease" ids="C0009373" disease_type="Disease or Syndrome" abbrv="">colonic disease</z:e> (CD) have an increased risk of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Eaden's meta-analysis has shown that the risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in UC patients is 2% at 10 years, 8% at 20 years and 18% at 30 years of disease duration </plain></SENT>
<SENT sid="2" pm="."><plain>It is now accepted that the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is equivalent in both (UC and CD) conditions </plain></SENT>
<SENT sid="3" pm="."><plain>Duration of disease is recognized to be the most important risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development </plain></SENT>
<SENT sid="4" pm="."><plain>Extent of disease in another major risk factor </plain></SENT>
<SENT sid="5" pm="."><plain>Most <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> arise in patients with <z:e sem="disease" ids="C0849867" disease_type="Disease or Syndrome" abbrv="">extensive disease</z:e>, which is generally defined as extension of <z:mp ids='MP_0001845'>inflammation</z:mp> beyond the hepatic flexure </plain></SENT>
<SENT sid="6" pm="."><plain>It was demonstrated that <z:mp ids='MP_0003305'>proctitis</z:mp> and <z:e sem="disease" ids="C0033252" disease_type="Disease or Syndrome" abbrv="">proctosigmoiditis</z:e> posed no increased risk for patients with UC </plain></SENT>
<SENT sid="7" pm="."><plain>Recent data from case control studies suggests that greater degrees of colonoscopic or histologically active <z:mp ids='MP_0001845'>inflammation</z:mp> are associated with an increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Recently, it has been proven that shortened tubular colon, <z:e sem="disease" ids="C0267466" disease_type="Disease or Syndrome" abbrv="">colonic stricture</z:e> and postinflammatory <z:mpath ids='MPATH_491'>polyps</z:mpath> should be considered strong risk factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development </plain></SENT>
<SENT sid="9" pm="."><plain>Primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> (PSC) in patients with UC is associated with substantial risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Screening colonoscopy should be performed in patients with UC after 8-10 years of disease </plain></SENT>
<SENT sid="11" pm="."><plain>The interval between surveillance examinations is dependent on each individual's personal risk factors </plain></SENT>
<SENT sid="12" pm="."><plain>In patients with a previous history of PSC, ongoing active <z:mp ids='MP_0001845'>inflammation</z:mp>, previous history of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or strictures, and strong family history of <z:e sem="disease" ids="C0346627" disease_type="Neoplastic Process" abbrv="">bowel cancer</z:e>, annual surveillance is recommended </plain></SENT>
<SENT sid="13" pm="."><plain>Colectomy is strictly recommended for patients who were diagnosed with flat high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and where the diagnosis was confirmed by expert gastrointestinal pathologists </plain></SENT>
<SENT sid="14" pm="."><plain>In patients with a biopsy specimen considered indefinite for <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, guidelines suggest colonoscopy between 3 and 12 months </plain></SENT>
<SENT sid="15" pm="."><plain>Multifocal low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (LGD) is a stronger indication for colectomy </plain></SENT>
<SENT sid="16" pm="."><plain>The optimal colonoscopic surveillance interval for patients who were diagnosed with a flat LGD is still unknown, but 3-6 months is often recommended </plain></SENT>
<SENT sid="17" pm="."><plain>Chemopreventive agents should be used to minimize the risk of developing <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in IBD patients </plain></SENT>
<SENT sid="18" pm="."><plain>It has been shown that <z:chebi fb="0" ids="6775">mesalazine</z:chebi> has a preventive effect for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
</text></document>